Endoplasmic reticulum (ER) stress is implicated in chronic kidney disease (CKD) development in patients and in animal models. Here we show that ER stress inhibition through 4-phenylbutyric acid (4-PBA) administration decreases blood pressure, albuminuria, and tubular casts in an angiotensin II/deoxycorticosterone acetate/salt murine model of CKD. Lower albuminuria in 4-PBA-treated mice was associated with higher levels of cubilin protein in renal tissue membrane fractions. 4-PBA decreased renal interstitial fibrosis, renal CD3+ T-cell and macrophage infiltration, mRNA expression of TGFβ1, Wnt signaling molecules, and ER stress-induced pro-inflammatory genes. CHOP deficient mice that underwent this model of CKD developed hypertension comparable to wild type mice, but had less albuminuria and tubular casts. CHOP deficiency resulted in higher nephrin levels and decreased glomerulosclerosis compared to wild type mice; this effect was accompanied by lower macrophage infiltration and fibrosis. Our findings portray ER stress inhibition as a means to alleviate hypertensive CKD by preserving glomerular barrier integrity and tubular function. These results demonstrate ER stress modulation as a novel target for preserving renal function in hypertensive CKD.
Sterol regulatory element binding protein (SREBP) is an important potential mediator of kidney fibrosis, and is known to be upregulated in diabetic nephropathy. Here we evaluate the effectiveness of SREBP inhibition as treatment for diabetic nephropathy. Type 1 diabetes was induced in uninephrectomized male CD1 mice with streptozotocin. Mice were treated with the SREBP inhibitor fatostatin for 12 weeks. At endpoint, kidney function and pathology were assessed. Fatostatin inhibited the increase of both isoforms of SREBP (1 and 2) in diabetic kidneys. Treatment attenuated basement membrane thickening, but did not improve hyperfiltration, albuminuria or kidney fibrosis in diabetic mice. Surprisingly, treatment of non-diabetic mice with fatostatin led to hyperfiltration and increased glomerular volume to levels seen in diabetic mice. This was associated with increased renal inflammation and a trend to increased renal fibrosis. Both in vivo and in cultured renal proximal tubular epithelial cells, fatostatin increased expression of the pro-inflammatory cytokine monocyte chemoattracant protein-1 (MCP-1). Thus, SREBP inhibition with fatostatin is not only ineffective in preventing diabetic nephropathy, but it also leads to kidney injury in non-diabetic mice. Further research on the efficacy of other SREBP inhibitors, and the specific roles of SREBP-1 and -2, in the treatment and pathogenesis of diabetic nephropathy need to be evaluated.
12 July 2020 in ACS Biomaterials Science & Engineering